Clareo Health | A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on June 24th, 2014 due to change in strategy of PF-03446962 clinical development. There were no safety or efficacy concerns regarding the study behind the decision to terminate the trial. The study was on temporary halt since March 10th and there are currently no patients on treatment or in the process of being randomized
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of locally advanced or metastatic liver cancer obtained by histology/cytology or by imaging
Documented progression on or after treatment with sorafenib, confirmed by the Investigator upon review of appropriate imaging documentation
Child Pugh Class A disease
ECOG \[Eastern Cooperative Oncology Group\] Performance Status (PS) 0 or 1
Mandatory tumor biopsy at study entry (pre-randomization, unless already collected after sorafenib progression but within 3 months of enrollment and no systemic anticancer therapies received)
You may not be if
Prior systemic treatment for advanced liver cancer other than sorafenib-including therapy
Prior local therapy within 2 weeks of starting the study treatment
Presence of main portal vein invasion by liver cancer
